Pulmocide announces today that it has commenced a human RSV challenge study
with PC786. PC786 is a novel, potent RSV L polymerase inhibitor which is administered
by the inhaled route of administration to enable delivery directly to the airways.
Recent phase 1 pharmacokinetic data indicates that PC786 has excellent lung
retention properties with minimal systemic exposure.